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Abstract
Introduction: There is a pressing need for effective measures to prevent the spread of cholera. Our systematic review
assesses the effects of chemoprophylaxis in preventing cholera among exposed contacts.
Methods and Findings: We considered published and unpublished reports of studies up to July 2011. For this we
searched: PubMed (1966 to July, 2011), Embase (1980 to July 2011), Cochrane Central Register of Controlled Trials (6;
2011), LILACS (1982 to July, 2011), the International Clinical Trials Registry Platform (July 2011) and references of identified
publications. We included controlled clinical trials (randomized and non-randomized) in which chemoprophylaxis was
used to prevent cholera among patient contacts. The main outcome measures were hospitalization and laboratory
diagnosis of cholera in contacts for cholera patients. We assessed the risk of bias. We identified 2638 references and these
included 2 randomized trials and 5 controlled trials that added up to a total of 4,154 participants. The risk of bias scored
high for most trials. The combined results from two trials found that chemoprophylaxis reduced hospitalization of
contacts during the follow-up period by 8–12 days (2826 participants; RR 0.54 95% CI 0.40–0.74;I
2 0%). A meta-analysis of
five trials found a significant reduction in disease among contacts with at least one positive sample who received
chemoprophylaxis during the overall follow-up (range 4–15 days) (1,414 participants; RR 0.35 95% CI 0.18–0.66;I
2 74%). A
significant reduction in the number of positive samples was also found with chemoprophylaxis (3 CCT; 6,918 samples; RR
0.39 95% CI 0.29–0.51;I
2 0%).
Conclusion: Our findings suggest that chemoprophylaxis has a protective effect among household contacts of people with
cholera but the results are based on studies with a high risk of bias. Hence, there is a need for adequate reliable research
that allows balancing benefits and harms by evaluating the effects of chemoprophylaxis.
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Introduction
As we advance into the 21st century, an estimated one billion
people remain without adequate access to safe water and
sanitation and vulnerable to cholera epidemics [1]. It is estimated
that there are 3–5 million cholera cases every year, leading to
100,000–130,000 deaths, mostly in Africa and Asia, and affecting
both children and adults [2,3]. The growing number of people
affected involving major cholera outbreaks are cause for concern
at the World Health Organization (WHO); WHO reported a 24%
an increase in reported cases for the 2004 to 2008 period
compared to the 2000 to 2004 period [4]. Most affected countries
report an overall cholera case-fatality rate (CFR) under 5%, but in
some locations the CFR approaches 50% during outbreaks,
affecting highly vulnerable groups [3].
Currently (2011) the world is facing the so called ‘‘seventh
cholera pandemic’’ that began in Indonesia in 1961 and is caused
by an El Tor biotype of Vibrio cholera serogroup O1. An
outbreak has happened in Haiti and it is of particular concern
because of the devastation associated to the earthquake on 12
January 2010 that dramatically increased the vulnerability to the
spread of cholera [5]. The strains of Vibrio cholera found in Haiti
belong to a category known as hybrids which produce the
classical type of cholera toxin and are a variant of the El Tor
biotype [6]. According to the Ministe ` r ed el aS a n t e ´ Publique et
de la Population (MSPP) of Haiti, from mid October 2010 to the
third week of June 2011, a total of 363,117 cholera cases were
reported in the country, of which 55% (191,508) were
hospitalized and 5,506 died; the overall case fatality rate was
1.5% [7].
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spread of cholera. Although there are effective and efficient
preventive measures, consisting of providing adequate access to
safe water and sanitation, health education and proper food
hygiene, in many settings such basic measures are difficult to
implement.
The Strategic Advisory Group of Experts (SAGE) on immuni-
zation recommended the use of immunization with cholera
vaccines in conjunction with other prevention and control
strategies, in areas where the disease is endemic [8]. Chemopro-
phylaxis refers to the administration of medication to prevent
disease or infection. In the case of cholera, healthy individuals are
given antibiotics with the aim of protecting them against the
disease, limiting the spread of the disease and curtailing an
epidemic. Multiple infections in the same household are common
due to shared sources of contaminated water and food. WHO does
not recommend chemopophylaxis arguing that ‘‘routine treatment
of a community with antibiotics, or mass chemoprophylaxis, has
no effect on the spread of cholera, can have adverse effects by
increasing antimicrobial resistance and provides a false sense of
security’’ [9]. In addition, chemoprophylaxis with antibiotics is
also limited by access, costs, and contraindications [9,10].
Nevertheless, large-scale selective antibiotic prophylaxis has
been provided to the contacts of people with cholera during
outbreaks, as part of comprehensive community interventions
[10]. Some experts argue that a well-targeted antibiotic prophy-
laxis can reduce direct human transmission of cholera [11], but it
is difficult to evaluate the role of chemoprophylaxis in limiting
cholera epidemics.
We conducted this systematic review of the findings of
randomized clinical trials (RCT) and controlled clinical trials
(CCT) to assess the effects of chemoprophylaxis and its
effectiveness in preventing cholera in patient contacts.
Materials and Methods
We conducted structured searches in PubMed (1966 to July 31,
2011), Cochrane Central Register of Controlled Trials (Central)
(6; 2011), LILACS (1982 to July 31, 2011), Embase (1980 to July
31, 2011), and Scirus (July 31, 2011) (Annex 1). We searched the
International Clinical Trials Registry Platform search portal of
WHO (ICTRP) to identify past and ongoing trials using the key
words ‘‘cholera’’ or ‘‘cholerae’’. References of identified publica-
tions were screened and relevant websites were searched
(document S1). We reached out to authors and relevant key
stakeholders to identify unpublished studies and related additional
data from manuscripts.
Inclusion criteria and outcomes
We included randomized clinical trials (RCT) and controlled
clinical trials (CCT) which assessed the effectiveness of antibiotics
in preventing cholera among patients’ contacts. We only
considered RCTs/CCTs using chemoprophylaxis for contacts
(children and/or adults) compared with no intervention, placebo,
or other chemoprophylaxis regimens. Studies in which the
intervention group included vaccines were excluded.
Clinical and bacteriological diagnoses of cholera (secondary
cases) were the main outcomes considered in the review regardless
of the microbiological method used to diagnose cholera. We
included those adverse events reported in CCT/RCTs and did not
search for additional adverse event studies or records. Due to
variations in outcome reporting, we collected data which provided
the number of subjects having at least one positive sample, the
number of total subjects as well as the total number of positive
samples, and the total number of samples obtained during follow-
up. In addition, we collected data from trials that included or
excluded contacts with positive samples on the first day of
treatment. Findings are presented according to categories that
were pre-specified by the trial.
Study selection
Two independent reviewers assessed separately the titles,
abstracts, and studies identified in the literature search (LR, EC).
All trials matching the inclusion criteria were screened by two
reviewers. Disagreements between reviewers were to be resolved
by consensus or eventually majority by involving a third author;
eventually the third author option was not required.
Data extraction
At least two reviewers (LR, EC, TPK, PRP) independently
extracted the relevant data using a predesigned data extraction
form; disagreements between reviewers were resolved by referring
to a third author. Key variables that were collected included
identification data of the paper, treatment characteristics (type of
intervention, dose, and duration), demographic variables (age,
gender), number of participants, patients lost to follow up,
proportion of patients with laboratory diagnoses of cholera
(secondary cases), the methodology of the diagnosis, and all
reported adverse events. Included studies were used to analyze the
type and frequency of adverse effects, we only used included
studies.
We performed an evaluation on the risk of bias for each trial
following the Cochrane Collaboration tool for the assessment of
these variables [12]. We also assessed inclusion and exclusion
criteria; sample size calculation; and baseline comparability of age,
gender, relevant clinical characteristics, and diagnoses. We
registered data in the studies table (Table S1).
We obtained outcomes data from published articles and
compared it using Review Manager Version 5.0 (RevMan 5).
We contacted authors to obtain additional information about their
studies.
Statistical analysis
We used the RevMan 5 software from the Cochrane
Collaboration to assist the statistical analysis. For dichotomous
primary outcomes the results, expressed as relative risk (RR) and
95% confidence intervals (CI), were calculated using the Mantel–
Haenszel random effects model. For the pooled analysis we
calculated the I square (I
2) statistic that describes the percentage of
total variation across studies attributed to heterogeneity [12]; low,
moderate, and high levels of heterogeneity are roughly estimated
as I
2 values of 25%, 50%, and 75%, respectively. Where necessary,
multiple arms of a study were combined grouping the relevant
interventions into a single group, and all relevant control
interventions as a single control group [12]. The PRISMA check
list is provided as suppoting information (Document S2).
Results
Characteristics of studies
We identified 2638 references of interest (Figure 1) through the
literature search and deemed relevant 16 studies of chemopro-
phylaxis amongst contacts of individuals diagnosed with cholera.
We included and analyzed 7 trials: two randomized controlled
trials (RCTs) and five controlled trials (CCTs), with 4.154
participants altogether (2606 of them received chemoprophylaxis)
(Table S1) [13–19]. Nine references did not comply with eligibility
criteria and were excluded (Table S2) [10,20–27].
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four CCTs were in Bangladesh [16], Pakistan [18], Ivory Coast
[17] and Peru [14]. One CCT allocated families, rather than
individuals, to prophylaxis [18]. One of the seven trials was
published in the 1960s [18], four in the 1970s [13,15,17,19], one
in the 1980s [16], and one in the 1990s [14]. The follow-up time
(range 8 to 15 days), as well as the number of stool samples
collected (range 0 to 15), varied among studies. A number of
studies included contacts having positive bacteriological cholera on
the first day, while others excluded such contacts. Outcomes were
also reported in various formats across the studies; few trials
reported clinical outcomes (Table S1).
Assessment of risk of bias
Overall the quality of the reporting and design of the RCTs was
poor (Table S3). Two studies were randomized controlled trials
[14,17] and five were controlled clinical trials [13,15,16,18,19].
We found one RCT with unclear risk of bias [14] and the
remaining six trials were scored as having a high risk of bias
mainly because of inadequate methods to generate the sequence of
randomization (alternation), lack of allocation concealment, and/
or incomplete outcome data. One trial [16] included a ‘‘no
treatment’’ arm with most patients receiving vitamins instead of an
inert placebo [13,15,17–19]. One study [17] reported data only
for those contacts that developed cholera. The majority of trials
did not provide a sample size framework and a scientific rationale
for the sample size determination.
Effects of Interventions
Overall chemoprophylaxis. The seven trials assessed the
effects of different medications (tetracycline, doxycycline,
ciprofloxacine, sulfadoxine) vs. vitamins (used as placebo) or no
treatment. They also determined effectiveness based on different
outcomes; data for each individual outcome were not available in
all trials (Table S4). Only one RCT used an adequate placebo
[14].
Clinical outcomes. Few trials reported data on clinical
outcomes, including adverse effects (Table S4). No reports of
mortality were found in any trial. When we pooled two trials
[16,17], chemoprophylaxis (which included tetracycline and
sulfadoxine) was significantly more effective in preventing
hospitalization of contacts during the follow-up (2826
participants; RR 0.55 95% CI 0.41 to 0.75; I
2 0%; Figure 2).
However, both RCTs did not provide sufficient information to
determine if the authors reported all cause hospitalizations or only
cholera related hospitalizations.
Bacteriological outcomes. Meta-analysis of five trials [13–
15,18,19] found a significant reduction in the rate of at least one
positive sample during the overall follow-up amongst contacts
receiving chemoprophylaxis compared with the control group
(1414 participants; RR 0.34 95% CI 0.18 to 0.66; Figure 3); there
was significant heterogeneity among the 5 studies (I2=74%,
P,0.01). Chemoprophylaxis was also found to reduce the total
number of positive samples (one patient could have multiple
positive samples on different days) (3 trials; 6918 samples; RR 0.39
95% CI 0.29 to 0.51;I
2 0%; Figure 4) [13,15,19]. When positive
samples of contacts from day one during the reported follow-up
period were included, we found that chemoprophylaxis reduced
the rate of contacts presenting at least one positive sample (2 trials,
832 participants; RR 0.40 95% CI 0.14 to 1.11;I
2 82%) [18,19]
and the overall rate of positive samples (4 trials, 8.885 samples; RR
0.34 (0.20 to 0.59;I
2 64%) [13–15,19]. Meta-analysis of trials that
reported data on 4, 7, and 15 days of follow-up are shown in Table
S4. When considering only trials assessing the effects of
tetracycline and doxycycline, the combination of tetracycline
and doxycycline prevented contacts from having positive samples,
Figure 1. Flow diagram of study selection process.
doi:10.1371/journal.pone.0027060.g001
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one positive sample amongst contacts (Table S4).
Vibrio cholera susceptibility. One RCT [14] reported that
V. cholera 01 strains isolated from index cases and household
contacts had in vitro susceptibility to ciprofloxacin (MIC, 0.007 mg/
mL). One CCT [13] concluded that all the strains of V. cholera
isolated during the study were biotype El Tor, with no indications
of emergence of resistant strains when sulfadoxine was used as a
single dose.
Adverse events. Few trials reported adverse events
[13,14,19] and none assessed systematically the specific adverse
effects observed. Reports noted that adverse events were mild, but
criteria and/or judgment with regards to categorization of the
severity were not explicit. In combining the data of two trials
[13,14] that assessed utcomes after two weeks of treatment, we
found no significant difference in the incidence of diarrhea; one
CCT [19] reported that 7.3% of contacts that received




This systematic review suggests that hospitalization of contacts of
cholera patients can be reduced by 26% to 60% with the
prophylactic administration of antimicrobial agents (the hospital-
ization rate was 4.4% versus 8.0%in the control group). The studies
available for analysis are a highly heterogeneous group that assessed
different interventions and different outcomes with different
methods and at different follow-up times, with a variety of sampling
methods and outcome reporting. Most of the studies focused on
microbiological outcomes, documenting the excretion of V. cholera
after chemoprophylaxis [13–15,18,19], but there is limited
information about impact. Household contacts were followed for
short periods of time. It is uncertain whether those who received
chemoprophylaxis ultimately had the same rates of cholera and
hospitalization compared to those in the control group. Other
limitations of this review mainly concern the methodological quality
and poor reporting of most of the included studies. Because most
studies were conducted during the 1960’s and 1970’s, it is likely that
the epidemiological conditions (e.g.resistance, dissemination pat-
terns) have changed. The external and internal validity of included
studies is likely compromised by factors that increase bias and
imprecision, with a failure to address clinically important outcomes
and adequate assessment ofthe balance between benefits and harms
for participating individuals or populations. Most clinical trials
included in the review were performed at a time when antibiotic
resistance to cholera was rare, although a number of studies
worldwide suggest an increase in resistance of V. cholera to several
antibiotics worldwide [28–41]. Some of those studies strongly
suggest that mass chemoprophylaxis, and nonselective chemopro-
phylaxis of adult family members, can contribute to the emergence
of resistance [38–40]. In addition, attempts to provide chemopro-
phylaxis to household contacts require resources and time, and may
have associated risks and result in unexpected harms. It is difficult
withtheavailabledatato draw conclusionsthat could be adequately
used to inform policy and practice.
The containment of cholera needs adequate scientific basis.
This review highlights knowledge gaps and provides recommen-
dations for future studies to address the impact of chemoprophy-
Figure 2. Prevention of hospitalization of contacts of cholera patients during the follow-up.
doi:10.1371/journal.pone.0027060.g002
Figure 3. Proportion of patients with at least one positive cholera sample during the overall follow-up.
doi:10.1371/journal.pone.0027060.g003
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nurseries, orphanages, nursing homes, and ships). Future studies
should evaluate the effectiveness of relevant existing and new
single dose therapeutic options (e.g. azythromycin). The effective-
ness of chemoprophylaxis in reducing hospitalization rates should
be confirmed in well designed and conducted RCTs of adequate
sample size. Longer follow-up periods than in the past studies are
needed to determine the effectiveness of antibiotics. It seems likely
that only large cluster randomized trials, using an appropriate
placebo can provide the data required to make informed decisions
regarding the use of prophylactic antibiotics in cholera outbreaks.
RCTs should also conform to the guidelines from the Consoli-
dated Standards of Reporting Trials (CONSORT) statement [42].
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